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bstract
The severe cardiotoxicity incurred due to doxorubicin limits the use of their therapeutic potential. The current study aims to investigate the
ardioprotective effect of concomitant administration of flax lignan concentrate (FLC) and omega-3-fatty acid (ω-3-FA) on myocardial damage
n doxorubicin-induced cardiotoxicity in Wistar rats. Cardiotoxicity was induced by intraperitoneal injection of doxorubicin (4 mg/kg) on day
th, 14th, 21st and 28th day in normal saline. Concomitant administration of FLC (500 mg/kg) and ω-3-FA (1 mL/kg) lowered TNF- level,
ormalized ST, QT and mean arterial blood pressure, elevation in endogenous enzymes levels such as glutathione and lowering in malondialdehyde,
uper oxide dismutase followed by normalized lipid profile and reduced the mortality rate. The treatment had antiapoptotic potential at cellular
evel also histopathology of heart tissue (light and electron microscopical). Thus concomitant action of FLC and ω-3-FA may be antioxidant,
ntihyperlipidemic, anti-inflammatory and anti-apoptotic actions seem to the probable mechanisms in doxorubicin induced cardiotoxicity. It can
e concluded that FLC and ω-3-FA both have distinct mechanism for cardioprotection and hence the additive effect was observed in the present
tudy due to concomitant administration of FLC and ω-3-FA.
 2013 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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isease; DHA, docosahexanoic acid; Dox, doxorubicin; ω-3-FA, omega 3 fatty
cid; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipopro-
ein; VLDL, very low density lipoprotein; SOD, super oxide dismutase; MDA,
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ABP, mean aterial blood pressure; ELISA, enzyme-linked immunosorbent
ssay; ROS, reactive oxygen species; TNF-, tumor necrotic factor-  level;
CG, electrocardiographic; TEM, transmission electron microscope.
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h.  Introduction
Flaxseed has been used as human food for thousands of
ears; industrial uses of flax oil have predominated since the
ndustrial revolution. There has been considerable interest in
he inclusion of flaxseed in western diet, medicinal food or
n the development of isolated and purified compounds for
ood, animal feed, and the improvement of human health.
laxseed seed with its high level of omega-3-fatty acid (ω-
-FA), assumes super food status. But due to the presence
f several antinutrients such as cynogenic glycosides, linatine
nti-vitamin B6, flaxseed is not generally regarded as com-
only edible food [1]. An array of therapeutic activities of
axseed is well proven one of them is antiatherosclerotic activ-
ty which is mainly attributed to secoisolariciresinol diglucoside
SDG) [2]. In our previous study, we have reported the cardio-
rotective activities in isoprenaline induced cardiotoxicity of
ax lignan concentrate (FLC) extracted from flaxseed [3] and
n vitro  antioxidant activity of SDG lignan is previously reported
4].
For many years, scientists were puzzled by the fact that
eart disease among Greenland Eskimos was extremely rare
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espite their consumption of a high fat, high-cholesterol
iet. Later research revealed that the Eskimos were pro-
ected by diets largely based on seals, whales and fish,
ll of which provide high intakes of omega-3 polyunsat-
rated fatty acids (ω-3-PUFA), especially eicosapentaenoic
cid (EPA) and docosahexanoic acid (DHA) resourced from
arine origin [5]. This observation established “Eskimo para-
ox” wherein little evidence of heart disease and low blood
holesterol levels was reported [6]. Now it is well estab-
ished that there is an inverse relationship between high fish
il consumption and mortality following cardiovascular dis-
ase (CVD). The mechanism by which ω-3-FA may reduce
isk for cardiovascular disease includes reduction of suscepti-
ility of the heart to ventricular arrhythmia, antithrombogenic,
ypotriglyceridemic, retardation of growth of atherosclerotic
laque, reduction of adhesion molecule expression, reduction
f platelet-derived growth factor, anti-inflammatory, promotion
f nitric oxide-induced endothelial relaxation and mild hypoten-
ion [7].
Despite of controversy about the mechanism of doxorubicin
Dox) on tumor cells, doxorubicin induced cardiotoxicity is a
ell established model to study the cardiovascular effects of
ifferent natural and synthetic drugs in rodents. Various mech-
nism of doxorubicin toxicity in rodents has been suggested.
oxorubicin administration increased oxidative stress due to
roduction free radicals and caused cardiac deficit of antiox-
dants. At the nuclear level, intercalation into DNA, leading
o inhibition of synthesis of macromolecules has been sug-
ested, which precipitate DNA abnormalities like alkylation,
rosslinking, strand separation and helicase activity. DNA dam-
ge may be initiated via  inhibition of topoisomerase II and
nduction of apoptosis in response to topoisomerase II inhibition
8]. There are several reports of reversal of doxorubicin car-
iotoxicity by natural products [9] including fish oil containing
-3-FA [10], apart from this model has been successfully used
n evaluation of cardioprotective action of number of extracts
rom medicinal plants such as Zingiber  ofﬁcinale  [11], garlic
12].
However, different types of events, such as anti-inflammatory,
nti-atherosclerotic and anti-immunomodulatory effects, have
ot yet been well explained and further focused studies are
equired to explore these properties to establish an opti-
ized conventional drug therapy for cardioprotection [13].
everal reports have been published, emphasizing that statins
lone are not sufficient and the use of combination therapy
ith ω-3-FA and statin is recommended for cardiovascu-
ar prognosis [14]. Nadtochiy and Redman [15] reported a
ery systematic approach for cardioprotective effects of the
editerranean diet explained, which is due to PUFA and
ifferent types of polyphenol, they possibly act through dif-
erent, distinct and convergent mechanisms. These findings
xplain the need for a novel design for the treatment of car-
iovascular disorder. Therefore, the objective of the present
tudy was to investigate the protective effect of concomitant
dministration of flax lignan concentrate and ω-3-FA on myocar-
ial damage in doxorubicin-induced cardiotoxicity in Wistar
ats.
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.  Materials  and  methods
.1.  Collection  and  authentication  of  plant
Authenticated seeds of Linum  usitatissimum  (Linn.) were
btained from Dr. P.B. Ghorpade, Principal, Scientist, Punjabrao
eshmukh Krushi Vidyapeeth, College of Agriculture, Nag-
ur, India and voucher specimen was deposited at the institute.
laxseeds were stored in cold room before processing. Further
rocessing for oil extraction was carried out at our Omega-3-oil
nit, Sangamner, Maharashtra, India.
.2.  Drugs  and  chemicals
ω-3-FA mainly containing docosahexaenoic acid derived
rom algal sources was obtained from Martek Biosciences Cor-
oration, Columbia, USA. Doxorubicin (Dox) was received as a
ift sample from Serum Institute of India, Pune, India. Absolute
lcohol (Changshu Yangyuan Chemicals, China) was purchased
rom respective vendors. n-Hexane, hydrochloric acid, sodium
ydroxide and sodium chloride of analytical grade were pur-
hased from Qualigene fine-chem. Ltd., Mumbai, India. Rat
umor necrotic factor-  kit (Thermo Scientific, Rat TNF-  kit,
ierce Biotech Int., Rockford, IL, USA), was purchased from
espective vendors. Triglycerides (TG), total cholesterol (TC)
nd high density lipoprotein (HDL-C) kits ware purchased from
ccurex Biomedical Pvt. Ltd., India. Epinephrine hydrochlo-
ide, super oxide dismutase (SOD) and malondialdehyde (MDA)
ere purchased from Sigma Chemical Co., USA. Reduced glu-
athione (GSH), 5,5′-dithiobis (2-nitro benzoic acid) (DTNB)
nd thiobarbituric acid (TBA) were obtained from Himedia,
ndia.
.3.  Preparation  of  ﬂax  lignan  concentrate  (FLC)
Preparation of flax lignan concentrate was carried out as
escribed previously [3]. Briefly, the flaxseed were subjected
or oil extraction by double cold pressed technique which
as carried out at Indian Council of Agricultural Research
nder National Agriculture Innovation Project, Omega-3-oil
nit, Sangamner, Maharashtra, India. In order to remove more
esidual lipids from the matrix use of non-polar organic solvent
uch as hexane in a soxhlet apparatus was used, as they might
nterfere with the analysis of lignans. In order to liberate SDG
rom its polymeric lignan precursor by breaking the ester-
inkages present in the complex, direct alkaline hydrolysis was
referred, hence defatted flaxseed cake was then hydrolyzed
ith 1 M aqueous sodium hydroxide for 1 h at room temperature
ith intermittent shaking, followed by extraction with 50%
thanol. In order to prevent the ionization of any functional
roups in the aliphatic and aromatic part of the SDG molecule,
he filtrate was acidified to pH 3 using 1 N hydrochloric acid.
he filtrate was concentrated in rotary evaporator. An additional
enefit of this process is the destruction of the cyanogenic
lycosides yielding an extract free of cyanogenic glycosides.
he yield of FLC was 14% (w/w). The powdered lignan rich
xtract was dissolved in distilled water to prepare the different
 and 
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oncentrations of FLC and used for pharmacological studies.
resh drug solution was prepared from each day.
.4.  Characterization  and  identiﬁcation  of  active
ompound in  FLC
Identification and quantification of SDG lignan content in
LC was carried out by using high pressure thin layer chro-
atography. SDG lignan content in FLC was found to be
0 mg/g [3]. Preliminary phytochemical analysis of FLC showed
he presence of flavonoids and phenolics [16]. In acute oral tox-
city studies, no mortality was observed in mice up to the dose
f 5000 mg/kg [3].
.5.  Research  protocol  approval
The experimental protocol was approved by the Institutional
nimal Ethics Committee (IAEC) constituted in accordance
ith the rules and guidelines of the Committee for the Purpose of
ontrol and Supervision on Experimental Animals (CPCSEA),
ndia (Approved protocol no-CPCSEA/2011/53; institutional
pproval no – CPCSEA/1999/100).
.6.  Experimental  animals
Male Wistar rats weighing between 200 and 220 g were pur-
hased from National Institute of Bioscience, Pune, India. The
nimals were housed at an ambient temperature (25 ±  2) ◦C
nd relative humidity (50 ±  2)% and light and dark cycle (12 h
ight/dark). The animals had access to pellet diet (Chakan oil
ills, Pune) and water ad  libitum.
.7.  Selection  of  dose  of  ﬂax  lignan  concentrate
Dose of FLC in present study was selected as reported pre-
iously [3,16].
.8.  Selection  of  dose  of  ω-3-FA
The study was carried out using three doses of ω-3-FA
.e. 0.5 L, 1 mL/kg and 2 mL/kg. As judged by the hemody-
amic parameters, 0.5 mL/kg had no significant action and 1 L,
 mL/kg gave same results, therefore 1 mL/kg was selected for
resent the study.
.9.  Experimental  design  and  protocol
After 2 weeks of an acclimatization period, animals were
andomly divided into five groups. Taking into account the
igh toxicity of doxorubicin and possible higher mortality, more
umber of animals were assigned to these groups. Each group
ontained a different number of animals. Animals received FLC
r ω-3-FA orally and doxorubicin by the intrapritoneally (i.p.)
oute as indicated below:
s
b
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Group  I:  Control group, animals received distilled water
orally as a vehicle for 7 weeks and normal saline
(i.p.) on the 7th, 14th, 21st and 28th day (n  = 6).
Group II:  Dox alone group, animals received distilled water
orally for 7 weeks and Dox (4 mg/kg, i.p.) on the
7th, 14th, 21st and 28th day in normal saline [17]
(n  = 12).
roup  III:  Dox + FLC group, animals received FLC
(500 mg/kg, p.o.) dissolved in distilled water
for 7 weeks and Dox (4 mg/kg, i.p.) on the 7th,
14th, 21st and 28th day in normal saline (n  = 9).
Group IV: Dox + ω-3-FA group, animals received ω-3-FA
(1 mL/kg, p.o.) for 7 weeks and Dox (4 mg/kg, i.p.)
on the 7th, 14th, 21st and 28th day in normal saline
(n = 9).
Group  V:  Dox + FLC + ω-3-FA group, animals received ω-3-
FA (1 mL/kg, p.o.) + FLC (500 mg/kg) for 7 weeks
and Dox (4 mg/kg, i.p.) on 7th, 14th, 21st and 28th
day in normal saline (n  = 9).
.10.  Survival  study
Mortality and general conditions of the animals were
bserved daily throughout the experimental period.
.11.  Tumor  necrotic  factor-α  level  (TNF-α)  by
nzyme-linked  immunosorbent  assay  (ELISA)
Myocardial tissue homogenate levels of TNF-  were deter-
ined by using an enzyme-linked immunosorbent assay
ccording to the manufacturer’s instructions. TNF-  level was
etermined from a standard curve. The concentrations were
xpressed as pg/mL.
.12.  Hemodynamic  parameters  and  left  ventricular
ontractile  function
At the end of the study period, animals were anaesthetized by
rethane (1.25 g/kg, i.p.). The right carotid artery of rat was can-
ulated for the measurement of systolic blood pressure (SBP),
iastolic blood pressure (DBP) and mean aterial blood pres-
ure (MABP). The polyethylene cannula (PE 50) was filled
ith heparinized saline and connected to pressure transducer.
he cannula was connected to a transducer and the signal was
mplified by means of a bioamplifier. The hemodynamic param-
ters were recorded by eight channel power lab (AD Instruments
ty. Ltd., Australia), having LABCHART-6 pro software. Left
entricular systolic pressure was measured by means of a Millar
ikro-tip transducer catheter (Model SRP-320, Millar instru-
ent, Texas) inserted into the left ventricle via  the right carotid
rtery and connected to a bioamplifier. dP/dtmax and left ventri-ignals (left ventricular systolic pressure and blood pressure)
y means of an acquisition data system (AD Instruments Pty.
td. with LABCHART 6 Pro software) as standardized in our
aboratory [18].
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.13.  Assessment  of  electrocardiographic  (ECG)
bnormalities
For the measurement of electrocardiogram the leads were
laced on the right foreleg (negative electrode), left foreleg
positive electrode), and right hind leg (neutral electrode). Elec-
rocardiographic changes and heart rate (HR) were recorded
sing 8 channels Power Lab System (AD Instruments Pty.
td., Australia) with LABCHART 6 Pro software. To study
oxorubicin-induced cardiotoxicity ST and QT intervals were
etermined as standardized in our laboratory [18].
.14.  Myocardial  endogenous  antioxidant  enzymes
A portion of myocardial tissue was individually homoge-
ized in 10% ice cold Tris–hydrochloride buffer (10 mmol/L,
H 7.4) in tissue homogenizer (Remi, India) and centrifuged
t 7500 r/min for 15 min at 0 ◦C. The clear supernatant was col-
ected after centrifugation and used for the assays of endogenous
ntioxidant enzymes. Superoxide dismutase (SOD) was deter-
ined by the method of Misra and Fridovich [19]. Glutathione
GSH) was determined by the method of Moron et al. [20]. Lipid
eroxidation (MDA) formation was estimated by the method of
later and Sawyer [21]. Total proteins were determined by the
ethod of Lowry et al. [22].
.15.  Lipid  proﬁle
The serum total cholesterol, triglycerides and HDL-
holesterol were quantified using enzymatic kits (Accurex
iomedical Pvt. Ltd., India) as per manufacturer’s instruction
anual. Very low density lipoprotein (VLDL) was calculated
sing Frieldwann’s equation [23].
LDL = TG
5
.
.16.  DNA  extraction  and  gel  electrophoresis
DNA was extracted from heart tissue using the phenol-
hloroform C-TAB method by using DNA isolation kit
Bangalore genei, India). 10 g of DNA was loaded onto 1%
garose gel and DNA electrophoresis carried out at 50–100 V
or 1–2 h. The gel was stained with ethidium bromide 0.5 mg/mL
nd examined under an ultraviolet transilluminator. The image
f the gel was captured using a gel documentation instrument.
.17.  Histopathology  of  heart
After recording of hemodynamic parameters the animals
ere euthanized, heart was removed and placed in 10% forma-
in solution. The organ specimens were subjected to dehydration
ith xylene (1 h each) and alcohol of strength 70%, 90% and
00% respectively, each for 1 h. The infiltration and impregna-
ion was carried out by treatment with paraffin wax twice for
ach time for 1 h. Parrafin wax was used to prepare paraffin L
olds. Specimens were cut into sections of 3–5 m thickness
a
s
t
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nd stained with hematoxylin and eosin (H and E). The sections
ere mounted by diestrene phthalate xylene. The parameters
f histopathology assessment of heart sections were myocardial
trophy, nuclear pyknosis, cytoplasmic eosinophilia and inflam-
ation. The grading system used for assessment of parameter
as [−−: absence of change, +: 0%–30% area shows changes,
+: 30%–60% area shows changes, and +++: 60%–100% area
hows changes] as described previously [3].
.18.  Ultrastructural  changes  in  rat  heart  in  doxorubicin
nduce cardiotoxicity  by  electron  microscopy
Myocardial tissue samples were fixed in 2.5%–3% gluter-
ldehyde in 0.1 mol/L phosphate buffer (pH 7.2) for 24 h at 4 ◦C
nd post fixed in 2% aqueous osmium tetraoxidein the same
uffer for 2 h. Dehydrated in series of graded alcohols, infiltrated
nd embedded in araldite 6005 resin or spur resin [24]. Ultra
hin (50–70 nm) sections were made with a glass knife of ultra
icrotome (Leica Ultra cut UCT-GA-D/E-1/00), mounted on
opper grids and stained with saturated aqueous uranyl acetate
nd counter stained with Reynolds lead citrate. Viewed under
lectron microscope (Hitachi, H-7500, Japan) at required mag-
ification (12,000×) as per the standard procedures at Ruska
abs, College of Veterinary Sciences, SVVU, Hyderabad, India
25].
.19.  Statistical  analysis
Data were expressed as the mean ±  S.E.M. Statistical anal-
sis was carried out by one-way ANOVA followed by post
oc Bonferroni test using graphpad prism 5.00 for Windows 7,
raphPad Software, San Diego, CA, USA, www.graphpad.com.
he P  value was considered significant when <0.05.
.  Results
.1.  General  observations  and  mortality
Within 3 weeks after the Dox administration, animals in the
ox and Dox + FLC groups developed scruffy, yellowish fur
round the eyes. Animals in the Dox group appeared sicker and
ore lethargic than the Dox + FLC group. However these symp-
oms were less prominent in Dox + ω-3-FA and concomitant
reatment with FLC and ω-3-FA group did not show any of these
hanges. After 3 weeks of treatment, the Dox and Dox + FLC
reated groups of animals had enlarged abdomens. In case of
ox + ω-3-FA and concomitant administration of ω-3-FA and
LC groups only slightly distended abdomen were observed.
he mortality rate was highest in the Dox alone group (50%).
here was 22% mortality in ω-3-FA treated and 33% mortality
n FLC treated group (Fig. 1). All animals in the control group
nd concomitant administration of ω-3-FA and FLC groups were
urvived. Heart weight/body weight ratio was decreased in Dox
reated group. Table 1 illustrates body weight and heart weight
n control and DOX-treated rats. After 4 weeks of injections,
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nig. 1. Effect of doxorubicin on survival rate after pretreatment with FLC, ω-3-
A and FLC + ω-3-FA.
ox-treated rats failed to maintain weight gains as observed in
ontrol rats (data not shown).
.2.  Tumor  necrotic  factor-α  level  (TNF-α)  by  ELISA
TNF-  level in myocardial tissue homogenate level was
ignificantly increased (P  < 0.001) in Dox alone group as
ompared to control group, whereas in all pretreated groups
NF-  was significantly decreased as compared to Dox alone
roup (P  < 0.001), however maximum significant decrease was
bserved in case of Dox + FLC + ω-3-FA group (Table 1).
i
c
i
(
able 1
ffect of FLC, ω-3-FA and FLC + ω-3-FA in doxorubicin induced cardiotoxicity on he
ipid profile and TNF- levels.
arameters Control Dox alone 
eart weight/body weight (×103) 3.097 ± 0.168 2.566 ± 0.342ns
SH (unit/mg protein) 28.21 ± 1.073 18.06 ± 1.373###
OD (unit/mg protein) 13.78 ± 0.518 3.005 ± 0.295###
DA (unit/mg protein) 9.474 ± 0.896 53.82 ± 2.657###
C (mg/100 mL) 37.18 ± 2.7 89.58 ± 10.35###
G (mg/100 mL) 68.5 ± 3.645 331.9 ± 30.35###
DL (mg/100 mL) 13.11 ± 1.036 8.717 ± 2.648 
LDL (mg/100 mL) 13.7 ± 2.256 66.38 ± 8.05###
NF- 42.22 ± 0.83 234.3 ± 3.36###
alues are expressed as mean ± S.E.M. Data was analyzed by One-way ANOVA fo
ipid peroxidation; SOD, superoxide dismutase; GSH, glutathione; TC, total choleste
ipoprotein; TNF-, tumor necrotic factor-alpha.
* P < 0.05 compared to Dox alone group.
** P < 0.01 compared to Dox alone group.
** P < 0.01 compared to Dox alone group.
## P < 0.001 compared to control group.
s, not significant.Human Wellness 2 (2013) 29–38 33
.3.  Hemodynamic  parameters  and  left  ventricular
ontractile  function
There was significant (P  < 0.001) alterations of the basal
emodynamic parameters such as SBP, DBP, MABP, LVSP
nd dP/dtmax in animals receiving doxorubicin alone. SBP
as significantly lowered (P  < 0.01) in Dox + ω-3-FA and
ox + FLC + ω-3-FA treated groups compared to Dox alone
roup, DBP was significantly (P  < 0.001) lowered in Dox + FLC
reated group and also (P  < 0.01) in Dox + FLC + ω-3-FA and
ox + ω-3-FA treated groups. In case of MABP, significant low-
ring was observed only in Dox + FLC + ω-3-FA treated group
ompared to Dox alone group (P  < 0.05). Similar results were
bserved in case of dP/dtmax. LVSP was significantly lowered
n all treated group compared to Dox alone group (P  < 0.001).
onsidering hemodynamic parameters and left ventricular con-
ractile function maximum significant decrease was observed
n case of Dox + FLC + ω-3-FA treated group than that FLC or
-3-FA alone group. Non-significant changes were observed in
ase of LVEDP in all groups (Fig. 2A–F).
.4.  Electrocardiographic  evaluations
Dox alone treated group showed significant (P  < 0.001) pro-
ongation of ST interval and QT interval of the ECG compared
o control group. On other hand, Dox + ω-3-FA and Dox + FLC
reated significantly (P  < 0.01) prevented changes in QT and
ox + ω-3-FA and Dox + FLC treated significantly (P  < 0.05)
revented changes in ST interval induced by doxorubicin,
hereas in animals which received concomitant administra-
ion of ω-3-FA + FLC showed maximum significant (P  < 0.001)
ffect in doxorubicin-induced prolongation of the QT and ST
nterval although not to normal. There were no significant
hanges in heart rate in all groups except in concomitant admin-
stration of ω-3-FA and FLC compared to Dox alone group
Fig. 2G and H).
art weight/body weight ratio, mortality rate, endogenous antioxidant enzymes,
ω-3-FA (1 mL/kg) FLC (500 mg/kg) ω-3-FA (1 mL/kg) + FLC
(500 mg/kg)
2.578 ± 0.280 2.779 ± 0.252 2.901 ± 0.267
24.65 ± 0.681* 21.86 ± 1.021 25.21 ± 1.979**
7.984 ± 0.622*** 9.585 ± 0.361*** 11.52 ± 0.624***
32.68 ± 1.885*** 24.51 ± 1.992*** 19.49 ± 2.976***
49.03 ± 10.41** 52.06 ± 3.098** 41.09 ± 2.979***
244.8 ± 22.32 204.5 ± 25.73** 178.3 ± 23.18***
13.35 ± 3.623 16.51 ± 2.597 22.62 ± 4.383*
40.9 ± 9.73 48.96 ± 5.02 35.66 ± 6.18*
188.7 ± 6.1*** 206.3 ± 2.01*** 172.0 ± 3.1***
llowed by post hoc Bonferroni test. P < 0.05 considered as significant. MDA,
rol; TG, triglycerides; HDL, high density lipoprotein; VLDL, very low density
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Fig. 2. Effect of doxorubicin on electrocardiographic abnormalities, hemodynamic changes and LV contractile function after pretreatment with FLC, ω-3-FA and
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SOD Dox alone group showed significant decrease (P  < 0.001)LC + ω-3-FA.
.5.  Myocardial  endogenous  antioxidant  enzymes
Cardiac content of GSH was reduced significantly (P  < 0.001)
n the Dox alone group as compared to control group. Animals
eceiving concomitant pretreatment of FLC + ω-3-FA showed
ignificantly (P  < 0.001) higher levels of GSH and Dox + ω-3-
A also showed significantly higher (P  < 0.05) levels of GSH as
ompared to Dox alone treated animals. However, GSH level in
he Dox + FLC group was non-significantly lowered than that of
a
t
(ontrol group. Cardiac levels of MDA contents were increased
ignificantly (P  < 0.001) in the Dox alone treated group com-
ared with control group. It was observed that pretreatment
ith FLC, ω-3-FA and concomitant administration of FLC
nd ω-3-FA significantly reduced the levels. Similarly in cases compared to control group and concomitant administra-
ion of FLC + ω-3-FA showed maximum significant increase
P < 0.001) than that of alone treatment (Table 1).
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Fig. 3. Effect of doxorubicin on DNA fragmentation after pretreatment with
FLC, ω-3-FA and FLC + ω-3-FA. M: marker, Lane 1: Control group, Lane 2:
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ane 5: Dox + FLC + ω-3-FA group.
.6.  Lipid  proﬁle
Serum triglycerides, total cholesterol, high-density lipo-
roteins and very low-density lipoproteins levels were analyzed
n all groups. Dox alone treatment caused significant (P  < 0.001)
ncrease in the serum triglycerides, total cholesterol, low density
ipoproteins and decrease in high-density lipoproteins non-
ignificantly. Although there was a trend toward a decrease in
ll lipids in the all groups, the prominent change was signifi-
ant only in the case of the concomitant administration of FLC
nd ω-3-FA in which total cholesterol was decreased signif-
cantly (P  < 0.001) and TG and VLDL levels also decreased
ignificantly (P  < 0.05). Total cholesterol levels were signifi-
antly decreased (P  < 0.01) in ω-3-FA and FLC treated group.
otal triglyceride levels were significantly decreased (P  < 0.01)
n FLC treated group. VLDL levels were significantly decreased
P < 0.05) only in case of concomitant administration of FLC and
-3-FA group (Table 1).
.7.  DNA  extraction  by  gel  electrophoresis
DNA fragmentation in heart tissue was analyzed with
garose-gel electrophoresis. Dox alone treated heart showed
arge amount degradation of DNA (Fig. 3, lane 2). How-
ver, Dox + FLC and Dox + ω-3-FA treated hearts had reduced
mount of DNA degradation (Fig. 3, lanes 3 and 4, respectively),
hereas concomitant administration of FLC and ω-3-FA + Dox
eart samples showed very little of DNA degradation (Fig. 3,
ane 5).
.8.  Histopathology  of  heart  tissueFig. 4 illustrates the section of heart tissues in control rat
A), in rat that received Dox alone (B), in rat that received
r
r
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ox + ω-3-FA (C), in rat that received Dox + FLC (D), in rat
hat received Dox + FLC + ω-3-FA (E). The histopathology of
he heart of control group showed absence of myocardial atro-
hy, nuclear pyknosis and inflammation (graded as −: absence
f changes). Doxorubicin administration in the control group
howed myocardial atrophy (+++), nuclear pyknosis (++), cyto-
lasmic eosinophilia (++) and inflammation (++) which means
hat 30%–60% area of the rat heart shown inflammation and
yknosis and myocardial atrophy in large areas of heart in rats.
n the other hand, myocardial atrophy (++), nuclear pyknosis
+), cytoplasmic eosinophilia (+) and inflammation (+) which
eans that 30%–60% area of the rat heart was inflammed,
yknosis and myocardial atrophy occurred in 30%–60% area
f heart in case of Dox + ω-3-FA treated group, similar results
ere observed in case of Dox + FLC treated group. Whereas,
yocardial atrophy (+) was observed in 30% area of heart and
uclear pyknosis (−), cytoplasmic eosinophilia (−) and inflam-
ation (−) were absent in Dox + FLC ++ ω-3-FA. The results
f histopathological analysis thus indicated that the rat heart did
et partially protected by pre-treatment of concomitant admin-
stration with ω-3-FA and FLC against the doxorubicin induced
ardiotoxicity.
.9.  Ultrastructural  changes  in  rat  heart  in  doxorubicin
nduced cardiotoxicity  by  electron  microscopy
Electron microscopy showed no cardiac injury in control
roup animals, as no mitochondrial damage was observed; dense
hromatin, prominent nucleus and nucleolus were observed
Fig. 4A1). The heart muscle samples from Dox alone group
howed characteristic features of cardiotoxicity which mani-
ested in the form of intracellular vacuolization, degeneration
f mitochondria, margnisation of chromatin and perinuclear
embrane dilation (Fig. 4B1). Dox + ω-3-FA and Dox + FLC
roup showed moderate changes as streaky vacuolization,
artial loss of architecture, moderate perinuclear dilatation
nd moderate disruption of chromatin material was observed
Figs. 3D1 and 4C1), whereas in case of Dox + FLC + ω-3-FA
roup, showed chromatin, preserved intramuscular bundle and
oderately less perinuclear space was observed (Fig. 4E1).
.  Discussion
In the present study, with 16 mg/kg cumulative dose of i.p.
dministration of the Dox, the sign of systemic and severe car-
iac toxicity could be observed. Fifty percent of the animals
ied before termination of the experiment in the doxorubicin
lone group possibly due to lethal toxicity, Jensen et al. [26] has
tated that after administration of doxorubicin, deaths may be
ue to some degree of bone marrow depression induced even
t a small total dose of doxorubicin [26,27]. In heart weight to
ody weight ratio, linear weight reduction was observed afteresulting in both heart weight and body weight loss. Similar
esults have been reported by other researchers in doxorubicin
nduced cardiotoxicity [28].
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Fig. 4. Effect of doxorubicin on histological changes of rat heart at 40× after pretreatment with FLC, ω-3-FA and FLC + ω-3-FA. Light electron microscopy: (A)
Control group, (B) Dox alone group, (C) Dox + FLC group, (D) Dox + ω-3-FA group, and (E) Dox + FLC + ω-3-FA group; Transmission electron microscopy: (A1)
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TNF-  is a sensitive anti-inflammatory biomarker for detec-
ing myocardial damages in doxorubicin induced cardiotoxicity
29]. Our findings showed restoration of TNF-  level in
LC alone and ω-3-FA alone and concomitant administration
f FLC and ω-3-FA against Dox-induced cardiotoxicity was
bserved.
Cardiac function protective effects of Dox + FLC alone and
ox + ω-3-FA alone and concomitant administration of FLC
nd ω-3-FA against Dox-induced cardiotoxicity were observed
n our study. The values of LVSP, +dP/dtmax, SBP, DBP, and
ABP increased in the Dox group which was partially restored
n these treated groups. Dox + ω-3-FA alone was more effective
han Dox + FLC alone in Dox induced cardiotoxicity. Concomi-
ant administration of FLC and ω-3-FA had slight additive effect
n cardiac function damage induced by Dox and can improve
ardiac function significantly.
The lengthening of the QT interval in ECG is regarded as an
ppropriate sign of myocardial injury induced by chronic treat-
ent of doxorubicin in rats [26]. Similar results were observed
n animal treated with doxorubicin alone when compared to
ontrol group. This indicates a protective effect of concomitant
dministration of FLC and ω-3-FA in doxorubicin-induced car-
iotoxicity. Non-significant changes were observed with respect
o heart rate.
a
e
boup, and (E1) Dox + FLC + ω-3-FA group.
Oxidative stress is a major risk factor in Dox-induced
ardiotoxicity [8], hence it was essential to investigate the oxi-
ant/antioxidant status of the rats. In the present investigation
DA was significantly elevated while GSH and SOD were
ignificantly reduced in Dox alone treated group compared to
ontrol group indicating an overt oxidative stress. These data
re in accordance with previous investigators [30]. In proceeding
ork, we reported cardioprotective activity of FLC against iso-
renalin induced cardiotoxicity due to antioxidant activity of
LC. The major chemical constituents present in the FLC (SDG
nd flavonoids alone or synergistically) may contribute to the
ntioxidant activity [3,4]. Pretreatment of rats with FLC alone,
-3-FA alone and concomitant administration of FLC and ω-3-
A reduced the oxidative stress produced by Dox.
Increased serum levels of triglycerides, cholesterol, high den-
ity lipoproteins and very low density lipoprotein were observed
n Dox alone group which indicated that doxorubicin may
nterfere with metabolism or biosynthesis of lipid. Similar obser-
ations were also reported by [9,31]. Pretreatment of rats with
LC alone, ω-3-FA alone and concomitant administration of
LC and ω-3-FA significantly prevented the myocardial alter-
tions and normalized the serum lipid profile. The protective
ffect exerted by FLC and ω-3-FA can be attributed to the com-
ination of antioxidant and lipid lowering actions of these agents
 and 
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[A.A. Zanwar et al. / Food Science
ndependently. The antiatherosclerotic [2] and antioxidant [3,4]
ctivities of FLC containing SDG have been reported. Holub
32] reported cholesterol and triglyceride lowering effect of
-3-FA containing algal DHA.
Although the mechanism for Dox-induced apoptosis is
nclear. It is observed that Dox strongly increased reactive
xygen species (ROS), a known trigger of apoptosis [33]. We
bserved Dox-treated heart samples higher degree of DNA
egradation which is an indication of oxidative stress and
ragmentation of chromosome possibly leading to apoptosis.
owever, Dox + FLC, Dox + ω-3-FA treated hearts had reduced
mount of DNA degradation, whereas concomitant administra-
ion of FLC and ω-3-FA + Dox-treated heart samples showed
ess degree of DNA degradation.
Administration of Dox produced severe changes in
yocardium with respect to myocardial atrophy, nuclear pykno-
is, cytoplasmic eosinophilia and inflammation which confirms
ardiotoxicity in rats. These changes are previously reported by
ther researchers [34]. Pretreatment of rats with FLC alone and
-3-FA alone exhibited comparatively less degree of damage
ompared to Dox alone group whereas in case of concomitant
dministration of FLC and ω-3-FA showed partial protection.
urther transmission electron microscopic studies provided cre-
ence to the cardioprotective effect. Restoration of vacuolization
nd reduction of intracellular damage in case of concomitant
dministration of FLC and ω-3-FA indicated protection in terms
f integrity of the subcellular structure in doxorubicin-treated rat
earts.
Micallef and Garg [35], showed cardioprotective bene-
ts of combined ω-3-PUFA and plant sterol supplementation
n hyperlipidemic individuals, wherein ω-3-PUFA and plant
terols as lipid-lowering agents provided greater risk reduc-
ion compared to either of the supplements alone. They used
on-pharmacological approach which showed lipid-lowering
enefits, down regulation of markers of systemic inflammation
nd reduction in overall cardiovascular risk. In present study,
harmacological approach was used by oral administration of
est substances (ω-3-FA and FLC).
.  Conclusion
In conclusion, the present findings demonstrated that, con-
omitant administration of FLC (500 mg/kg) and ω-3-FA
1 mL/kg) lowered TNF-  level, normalized ST, QT and MABP,
levation in GSH and MDA, SOD lowered and normalized lipid
rofile. The treatment provided protection from DNA degra-
ation at cellular level. Histopathology of heart tissue (both
ight and electron microscopical) confirmed the cardioprotective
ffect. The concomitant treatment reduced the mortality due to
ox administration. Thus antioxidant, antihyperlipidemic, anti-
nflammatory and anti-apoptotic actions seem to be the probable
echanisms in doxorubicin induced cardiotoxicity. Hence, it can
e concluded that FLC and ω-3-FA both have distinct mecha-
ism for cardioprotection and the additive effect was observed
n the present study due to concomitant administration of FLC
nd ω-3-FA. These data suggest a possible usefulness combina-
ion of FLC and ω-3-FA as a cardioprotective agent. The study
[
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eveals the role of flax lignan concentrate and ω-3-FA in pre-
enting doxorubicin-induced cardiotoxicity. Additional clinical
rials using this combination to further extrapolate these exper-
mental results are necessary, also more molecular studies to
eveal the underlying mechanisms in this direction is warranted.
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